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Platelet activating factor (PAF) as a mediator of injury in nephrotic
nephritis. Release of acetyl glyceryl ether phosphoryicholine,
platelet—activating factor (PAF), has been demonstrated to be associ-
ated with glomerular inflammatory damage in acute serum sickness.
Moreover, PAF can increase glomerular permeability to proteins and
induce mesangial contraction. Thus PAF might be a good candidate as
a mediator of glomerular damage. However the in vivo evidence that
PAF might cause glomerular injury is lacking. To evaluate if PAF has a
major role in promoting glomerular inflammatory reaction and fibrin
deposition, we studied the effect of a molecule, L-652,73l, which blocks
the PAF receptor, on the evolution of an experimental model of
anti-glomerular basement membrane (anti-GBM) glomerulonephritis
(ON). ON was initiated by sheep—anti-rabbit nephrotoxic serum. A
proliferative GN regularly occurred in which heavy proteinuria, intra
and extracapillary proliferation of resident and inflammatory cells and
fibrin deposition in Bowman's capsule were the prominent findings. Our
results showed that the PAF receptor antagonist reduces the glomerular
damage in anti-GBM GN, supporting the hypothesis that PAF is indeed
a mediator of glomerular inflammatory reaction. PAF receptor blocking
prevented renal function deterioration in the early phase of the disease,
probably preserving glomerular hemodynamics. In the delayed phase of
the disease the PAF receptor antagonist reduced proteinuria and
prevented renal function deterioration and fibnn deposition. These
effects appear to be mediated by an inhibitory action of PAF receptor
blocking on macrophage accumulation and activation.
Rabbits injected with sheep—anti-rabbit nephrotoxic serum
(NTS) develop a proliferative glomerulonephritis with fibrin
deposition at glomerular level and progressive deterioration of
renal function [1, 2]. Fibrin formation in Bowman's space is the
prominent feature in this disease and causes capillary lumen
obliteration with a decrease of glomerular filtration rate (GFR).
The sequence of events is the following: the heterologous
antibody binds to the kidney glomerular basement membrane
(GBM) within one hour from the injection of antiserum and
induces an acute damage (heterologous phase) mediated by
complement and polymorphonuclear cells [3, 4]. Tn this phase
proteinuria and decrease in GFR occur within few hours in
association with the peak of polymorphonuclear cell accumu-
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lation. The delayed phase of the disease (autologous phase) is
due to host's immune response to heterologous antibody bound
to the GBM. In this phase proteinuria and renal insufficiency
are associated with macrophage infiltration, fibrin formation
and extracapillary proliferation [5—8]. The mechanism respon-
sible for the formation of fibrin is poorly understood. It has been
proposed that the increase in glomerular capillary permeability
due to interruption of the GBM allows the passage of fibrinogen
in extravascular space [9]. Blood derived cells that infiltrate the
glomerular tuft may participate to fibrin formation [6, 7, 10—12].
Recent studies indicate that the deposition of fibrin in
Bowman's capsule might be the result of macrophage activation
which generates procoagulant activity [13, 141. The signal(s) for
macrophage accumulation, that is complement independent,
has not been identified. We have focused our attention on acetyl
glyceryl ether phosphorylcholine, also known as platelet acti-
vating factor (PAP). PAF is a lipid mediator of inflammation,
released from a variety of cell types including platelets, mono-
cytes and glomerular cells [15—17] that induces macrophage
activation [18] and increases vascular permeability [19, 20].
Studies on acute serum sickness indicate that the deposition of
circulating immune complexes at glomerular level and the
subsequent events leading to fibrin formation are associated
with platelet activation induced by a mechanism related to the
degranulation of IgE-sensitized basophils and PAP release
[2 1—23]. On the basis of these data it has been suspected that
PAF may be one of the mediators of glomerular inflammatory
reaction in proliferative glomerulonephritis. However the in
vivo evidence that PAP causes glomerular injury is lacking. Our
aim was to establish if PAF is a mediator of inflammatory injury
and fibrin deposition at glomerular level. For this purpose we
used a model of nephrotoxic nephritis induced in rabbits by
injection of anti-GBM antiserum. The injection of the antiserum
is followed by the development of a severe proliferative gb-
merulonephritis with large crescents in more than 70% of
glomeruli and abundant fibrin deposits in about 100% of
glomeruli. To obtain information on the possible role of PAP in
vivo we evaluated the effect of a PAF receptor antagonist on the
evolution of the disease. Specifically, we studied the effect of
blocking PAF receptor on membrane permeability to proteins,
glomerular cellularity and fibrin deposition and GFR.
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Methods
Preparation of sheep—anti-rabbit GBM antiserum
Rabbit kidneys were stored in ice—cold Krebs—Ringer phos-
phate buffer (KRB) (120.29 mrvi NaC1, 4.82 mM KCI, 1.21 mM
MgSO4 and 15.6 m phosphate buffer pH 7.4) prior to process-
ing. The renal capsules were removed and the medulla was
dissected away from the cortex and discarded. The cortex was
finely minced into I to 2 mm fragments with a razor blade, and
the glomeruli were separated from the residual cortical tissue
pushing the homogenate through a series of 80 and 120 mesh
sieves and collected on a 140 mesh sieve. The isolated glomeruli
were sonicated repeatedly and washed by centrifugation in
order to isolate GBM. Particulate GBM was emulsified in
complete Freund's adjuvant and then injected into sheep.
Repeated boosting immunizations were done every two weeks
and blood samples were collected at weekly intervals for the
estimation of anti-GBM antibody titers. The serum was heated
at 56°C for 30 minutes and absorbed with rabbit erythrocytes
and filtered by a 0.2 m syringe filter before injecting into
rabbits.
Characteristics of the animal model
The capacity of the antiserum to bind to the GBM in vivo and
to produce glomerular damage was investigated injecting dif-
ferent doses of the antiserum into normal rabbits. The amount
of I ml of antiserum/kg body wt was able to induce a severe
crescentic glomerulonephritis associated with a marked renal
function impairment within 15 days. The heterologous phase
developed within the first 24 to 48 hours from the injection of
antiserum. Glomerular hypercellularity due especially to poly-
morphonuclear leucocyte infiltration into the glomerular tuft
and deposition of proteinaceous material in Bowman's space
were observed. Tubular damage, characterized as casts in the
tubular lumen, was also present. The autologous phase started
after six days from the NTS injection. All glomeruli revealed a
significant and diffuse hypercellularity mainly consisting of
mononuclear inflammatory cells. With time a progression of
glomerular changes was observed: after eight days Bowman's
space appeared to be filled with fibrin. Crescent formation
started around day 10. By immunofluorescence (IF), all glomer-
uli exhibited a strong linear deposition of rabbit IgG and, to a
lesser extent, of sheep IgG along the GBM as typically ob-
served in anti-GBM glomerulonephritis. Atrophic changes, red
blood cells, casts and perhaps some areas of necrosis were also
present in several tubules.
A moderately severe inflammation and fibrosis were detected
in the interstitium. A severe proteinuria and renal failure were
associated with the morphological changes both in the heterol-
ogous and autologous phase.
Platelet—activating—factor receptor antagonist
The compound (trans-2,5-bis [3,4,5,-trimethoxyphenyl] tetra-
hydrofuran), is reported to be a PAF receptor antagonist [24,
25]. The efficacy and specificity of L-652,731 has been demon-
strated both in vitro and in vivo [24, 25]. The PAF antagonist
effectively inhibits platelet—aggregation induced by PAF but not
platelet aggregation induced by ADP, collagen, thrombin, ara-
chidonic acid (AA) and Ca + ionophore A23 187. In addition, in
vivo the PAF receptor antagonist at a dose of 10 to 20 mg/kg in
rats inhibits the PAF-induced cutaneous and systemic vascular
permeability and neutropenia. L-652,73l also inhibits PAF-
induced severe hypotension in rats.
In our experiments carried out in vitro, L-652,73 1 selectively
inhibited, in a dose—related manner (the 1C50 values ranged
between 1.0 to 2.0 sM), the irreversible aggregation of rabbit
platelet—rich plasma (PRP) induced by threshold aggregating
concentration (TAC) [26] of PAF (Fig. 1). Moreover ex vivo 10
to 100 times higher concentrations of PAF are necessary to
induce irreversible platelet aggregation in PRP of rabbits treated
with L-652,73 1 than in control animals (Fig. 2). We also showed
(Fig. 3) that L-652,731 effectively and significantly prevents the
acute transient neutropenia and thrombocytopenia induced by
intravenous injection of PAF—0.8 pg/kg [201—in normal rab-
bits.
Experimental design
Male, New Zealand White rabbits (Charles River Italia
S.p.A., Calco, Italy) weighing 2 to 2.5 kg were used. A group of
control rabbits (group 1) was studied to evaluate the effect of
L-652,731 (10 mg/kg body wt for 3 days) on renal function. Four
groups of nephritic rabbits were also studied: 12 rabbits (group
2) received i.v. 1 mI/kg body wt of sheep—anti-rabbit nephro-
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Fig. 1. In vitro effects of L-652,731 on PA F-induced platelet aggrega-
tion. Representative tracings of platelet aggregation induced by thresh-
old aggregating concentration (TAC) of PAF (15 nM) in rabbit PRP. The
TAC was defined as the smallest concentration of PAF which gave
irreversible platelet aggregation starting within three minutes of addi-
tion of the aggregating agent to PRP. L-652,731 was dissolved in 0.2%
DMSO and preincubated for one minute at 37°C before platelet chal-
lenge with PAF.
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toxic serum (NTS) that was given in three administrations at
intervals of one hour between the first and the second shoot,
and 40 minutes between the second and the third one. Rabbits
also received orally the vehicle of the PAF receptor antagonist
(5% carboxymethyl cellulose). Twelve rabbits (group 3) were
administered PAF receptor antagonist L-652,731 10 mg/kg body
wt orally, twice daily (starting from 1 hr and 30 mm before the
NTS injection) for 10 days. All the animals were sacrificed at
day 10. Two additional groups of six rabbits each (groups 4 and
5) were treated with NTS plus vehicle or NTS plus L-652,73 1,
and were killed after 24 hours to examine renal histology during
the heterologous phase of the disease.
Proteinuria
Rabbits were housed in metabolic cages that allowed collec-
tion of the final 24-hour urine sample. Protein concentrations
were determined on days 1, 4, 7 and 10 by the modified
Coomassie blue G, dye—binding assay for proteins [27]. Values
were calculated using bovine serum albumin (Sigma Chemical
Co., St. Louis, Missouri, USA) as standard curve.
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Creatinine clearance
Serum and urine creatinine were determined by the alkaline
picrate method [28], and creatinine clearance was calculated in
the usual manner.
Light microscopy
Fragments of renal cortex were fixed in Dubosq—Brazil fluid
(80% alcohol, 150 ml; formol, 60 ml; acetic acid, 15 ml; picric
acid, 1 g) and embedded in paraffin. Sections of 3 m were
stained with hematoxylin and eosin, Masson's trichrome, peri-
odic acid staining and Fraser—Lendrum staining for fibrin. Each
biopsy included at least 100 glomeruli. Glomerular endocapil-
lary hypercellularity was quantitated by a scoring system from
0 to 3+ (0, no hypercellularity; 1+, mild hypercellularity; 2+,
moderate and diffuse hypercellularity; 3+, marked and diffuse
hypercellularity). The percentage and the type (segmental or
circumferential) of crescents affecting the glomeruli were as-
sessed. Fibrin deposits, revealed by Lendrum stain, were
graded from 0 to 4+ (0, no fibrin; 1+, ito 25% of glomeruli with
fibnn deposits; 2+, 25 to 50% of glomeruli with fibrin deposits;
3+, 50 to 75% of glomeruli with fibrin deposits; 4+, 75 to 100%
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Fig. 2. Effects of oral administration of vehicle (A) or L-652,731 (10 mg/kg) (B) to healthy rabbits on PAF-induced aggregation ex vivo.
Representative tracings of different platelet response in the two conditions upon challenge with different concentrations of PAF.
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Fig. 3. Effect of L-652,731 on the acute reversible neutropenia and
thrombocytopenia induced by intravenous injection of PAF in normal
rabbits. The administration of PAF (0.8 pg/kg) in normal rabbits
induced an acute reduction in neutrophil and platelet count occurring
within five minutes from the intravenous injection (means SD of 3
animals are shown by empty bars). Oral administration of L-652,73 1(10
mg/kg) two hours before the PAF injection significantly protected
rabbits from both neutropenia and thrombocytopenia (means SD of 3
animals are shown by dotted bars). Data are expressed as percentage of
pre-challenge neutrophil and platelet counts. < 0.05, < 0.01 in
comparison with the values obtained in animals which did not receive
PAF receptor antagonist.
of glomeruli with fibnn deposits). Tubular changes (atrophy,
degeneration, red blood cells and casts) and interstitial inflam-
mation or fibrosis were graded from 0 to 4+ (0, no changes; 1+,
changes affecting 25% of sample; 2+, changes affecting 25 to
50% of sample; 3+, changes affecting 50 to 75% of sample; 4+,
changes affecting 75 to 100% of sample).
Immunofluorescence
Studies were carried out on fresh frozen tissue. Sections of 3
m were cut and stained with fluorescein isothiocyanate con-
jugated to antibodies to sheep IgG, rabbit IgG and C3 (N.L.
Cappel Laboratories Inc., West Chester, Pennsylvania, USA).
Sections were rinsed in phosphate buffer saline pH 7.4 for 45
minutes at room temperature and examined in a Leitz orthomat
microscope under ultraviolet light (Ernst Leitz, Wetzlar, West
Germany).
Statistical analysis
Results were analyzed by Duncan's multiple range test and
Student's t-test. Results are expressed as mean 1 SD. P values
under 0.05 were considered to be statistically significant.
Results
Proteinuria
A time course of anti-GBM induced proteinuria was studied
from day 1 to 10. The administration of NTS caused a statisti-
cally significant increase in protein excretion in respect to
normal values that was maximal over the first 24 hours (3186.6
1148.2 vs. 22.6 9.4 mg124 hr, P < 0.001). On day four,
protein excretion normalized to values fully comparable to the
control ones (28.3 10.8 mg124 hr). By the seventh day
proteinuria newly increased (2356.5 405.1 mg124 hr), and it
was also greatly elevated on day 10, remaining significantly
different from normal values (1256.5 370 mg/24 hr, P <
0.001). The course of protein excretion did not change during
the evolution of the disease in rabbits treated with the PAF
receptor antagonist in comparison with animals which did not
receive the drug, except on day 10 when a significant reduction
of proteinuria was observed in the first group (860.2 345.2 vs.
1256.5 370 mg/24 hr; P < 0.01; means are representative of 12
animals).
Histological studies
A total number of 36 rabbits were used for histological
studies: 12 for the heterologous phase and 24 for the autologous
phase. The examination of the kidneys at light microscopy 24
hours after the injection of NTS revealed severe glomerular and
tubular changes. Polymorphonuclear cell infiltration into the
glomerular tuft and deposition of proteinaceous material in
Bowman's space as well as red blood cells and cast formation in
the tubular lumen were observed (Fig. 4A). The administration
of PAF receptor antagonist markedly reduced the tubular
damage and the glomerular hypercellularity (Fig. 4B). A scoring
system, as described in Methods, was also used to quantify the
degree of the severity of glomerular and tubular damage in the
heterologous phase of the disease. Based on this scoring system
a milder glomerular hypercellularity was observed in the PAF
receptor antagonist treated group in comparison with NTN
rabbits receiving the vehicle (1.2 0.4 versus 2.3 0.8, P <
0.05). Similarly, tubular changes were less severe in NTN
rabbits treated with L-652,731 in respect to NTN rabbits
receiving the vehicle alone (0.7 0.3 vs. 2.9 1.6, P < 0.02).
In the autologous phase of the disease abundant deposits of
fibrin (Fig. 5A), as revealed by Lendrum stain, were found to be
associated with a large number of crescents in about 80% of
glomeruli (score: 3.5 0.6); this percentage decreased to 26.4%
in animals treated with the PAF receptor antagonist (score: 1.4
1.6, P < 0.001 in respect to NTN rabbits receiving the vehicle
alone). Moreover whereas the percentage of segmental and
circumferential crescents was of the same order in animals
treated with NTS plus the vehicle, a prevalence of segmental
type of crescents (17.1 9.5%) was observed in animals that
received PAF receptor antagonist (Fig. SB).
By immunofluorescence all glomeruli in rabbits treated with
NTS alone exhibited a strong linear deposition of sheep IgG in
the heterologous phase (Fig. 6A). In the autologous phase a
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Fig. 4. A. NTN heterologous phase: A glomerulus with polymorphonuclear cell infiltration and proteinaceous material in Bowman's space.
Proteinaceous casts are also present in the distal tubular lumens (trichrome stain x 225). B. NTN heterologous phase in animals treated with PAF
receptor antagonist. Glomerular and tubular changes are less pronounced than in NTN animals (trichrome x 225).
Fig. 5. A. NTN autologous phase: the glomerulu shows large circumferential crescents associated with a large amount of fibrin in Bowman's
space (trichrome x 215). 8. NTN autologous phase in animals treated with PAF receptor antagonist. The glomerulus shows the absence of
extracapillary proliferation and fibrin in Bowman's space (trichrome x 215).
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Fig. 7. Intense linear deposition of rabbit IgG during the autologous phase of the disease in glomeruli of NTN rabbits receiving the vehicle alone
(A) or given PAF receptor antagonist (B) (FITC anti-rabbit IgG X 380).
diffuse linear deposition of rabbit IgG (Fig. 7A) and C3 was before and 2.21 0.64 after the administration of the corn-
detected. The administration of PAF receptor antagonist did pound—b mg/kg orally twice a day—for 3 days).
not modify the intensity of immunofluorescence pattern in both Renal function measured as creatinine clearance was dramat-the heterologous and the autologous phase of the disease (Figs.
6B and 7B). ically impaired 24 hours after the NTS injection in respect to
basal values (mean SD: 0.27 0.22 vs. 2.57 0.57 mb/mm/kg
body wt, P < 0.001). The administration of PAF receptor
antagonist significantly increased the GFR (2.79 0.95
Role of PAF in rabbit NTN 1253
Fig. 6. Strong linear staining of sheep IgG along the glomerular basement membrane in glomeruli of NTN rabbits during the heterologous phase
of the disease. The intensity of immunofluorescence staining is indistinguishable in glomeruli of NTN rabbits receiving the vehicle alone (A) as
compared with NTN rabbits treated with PAF receptor antagonist (B) (FITC anti-sheep IgG x 390).
Renal function
L-652,731 did not influence renal function measured as cre-
atinine clearance in normal rabbits (mean SD: 2.05 0.22
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ml/minlkg body wt, P < 0.001) as compared with NTN rabbits
which did not receive the drug (Fig. 8).
On day four the GFR spontaneously recovered (2.35 0.70
mllminlkg body wt), but it decreased again during the autolo-
gous phase of the disease (day 7: 0.67 0.45; day 10: 0.74
0.44 mI/mm/kg body wt, P < 0.001 for both times as compared
with basal values).
Again the administration of PAF receptor antagonist pro-
tected the animals from renal function deterioration (day 7: 2.65
0.90, P < 0.001 and day 10: 1.78 1.20 mI/mm/kg body wt,
P < 0.01 as compared with NTN rabbits which did not receive
the drug) (Fig. 8).
Discussion
The present results show that PAF receptor—antagonist
L-652,731 reduces the glomerular damage in nephrotoxic
nephritis. These findings provide a direct evidence that PAF is
involved in glomerular inflammatory reaction and suggest that
PAF can be added to the list of already recognized mediators of
injury in proliferative glomerulonephritis. The effects of PAF
receptor antagonist appear to be different in the heterologous
and in the autologous phase of the disease.
In the heterologous phase glomerular permeability to proteins
is not significantly different in NTN receiving the vehicle alone
in respect to NTN animals which were treated with PAF
receptor antagonist. These findings suggest that protein excre-
tion in the heterologous phase of NTN is sustained by changes
in the permeability properties of glomerular filtering membrane
which are not directly related to the generation or release of
PAF. Actually early increase in glomerular capillary permeabil-
ity to proteins occurs within the first 24 hours from the injection
of antiserum, as documented in the present experiments, and
appears to be a classical antibody—mediated complement—neu-
trophil lesion [4]. This phenomenon is prevented by polymor-
phonuclear cell depletion [4], indicating that proteinuria in the
early phase of anti-GBM nephntis in rabbits is likely to be
mediated by a neutrophil.-dependent enzymatic damage to
glomerular capillary wall which follows complement activation.
At variance with the effect on proteinuria, PAF receptor
antagonist effectively prevents renal function deterioration ob-
served in the early phase of the disease. Within 24 hours from
the injection of nephrotoxic serum, rabbits develop a transient
pronounced decrease in GFR. The renal function deterioration
is almost completely prevented by blocking the PAF receptor.
These data would indicate that PAF has a direct role in the
derangement of renal function seen in the heterologous phase of
NTN. PAF may induce a reduction in GFR either directly
through a contraction of mesangial cells [29] with the conse-
quent decrease in glomerular surface area, or indirectly via
activation of arachidonate cascade and synthesis of vasoactive
metabolites [30]. It has indeed been found that PAF causes a
dose—dependent increase in the metabolism of AA in isolated
perfused kidney associated with an increase in renal vascular
resistance [30].
The favorable effects of PAF receptor antagonist are even
more pronounced in the autologous phase of the disease. Ten
days after the injection of nephrotoxic serum, animals treated
with the PAF receptor antagonist had a significant reduction in
proteinuria as compared with NTN animals receiving the vehi-
cle alone. Altogether these findings would indicate that in the
autologous phase of the disease PAF may be one of the
mediators of increased glomerular capillary permeability to
proteins. That PAF can increase the glomerular capillary per-
meability to macromolecules has been demonstrated by two
recent papers. Camussi and coworkers [20] have found that
PAF infusion induces a transient proteinuria in rabbits, and this
phenomenon is associated with the deposition of platelet—de-
rived cationic proteins within the glomerular capillary wall.
Proteinuria in this model is probably the result of the neutral-
ization of glomerular fixed anionic charges after binding to
cationic proteins released from PAF stimulated cells. In iso-
lated perfused rat kidney Pirotzky and coworkers [19] found
that PAF increases vascular permeability even independently
from the presence of platelets or neutrophils. The present data
that the administration of a PAF receptor antagonist signifi-
cantly reduces proteinuria offer a proof that these mechanisms
might operate in vivo. Another mechanism through which PAF
may increase glomerular permeability in this model could be its
effect on macrophages. From the first demonstration of
Schreiner and coworkers [6] that blood—borne mononuclear
phagocytes infiltrate the glomerular tuft and participate in the
local inflammatory reaction, a considerable amount of data
have been accumulated which converge to indicate that macro-
phages directly cause glomerular injury and proteinuria. Since
PAF is a potent chemotactic agent on monocytes [31, 32] and
promotes their recruitment at the site of inflammatory reaction,
it is conceivable that the inhibition of PAF activity in the
autologous phase of nephrotoxic nephritis is beneficial because
it limits the accumulation of macrophages within the glomerular
tuft. This interpretation is suggested by our results showing a
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Fig. 8. Rena! function measured as creatinine clearance at various
days of the disease in NTN rabbits receiving the vehicle alone (empty
bars) and NTN rabbits treated with L-562,731 (slashed bars). Mean
normal value SD was 2.57 0.57 ml/min/kg body wt. *f < 0.01,
<0.001 in comparison with NTN rabbits receiving the vehicle alone.
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marked reduction of extracapillary cell proliferation. It is now
well established that macrophages participate in the develop-
ment of glomerular extracapillary proliferation, first accumulat-
ing in the glomerulus and then migrating into Bowman's space
where they transform themselves and accumulate to form
crescents [71. Most direct evidence that PAF might be regarded
as a mediator of injury in this model is provided by data
showing that renal function does not progressively deteriorate
during the autologous phase of the disease in animals treated
with the receptor antagonist as it does in NTN rabbits receiving
the vehicle alone. The mechanism responsible for preserving
renal function after PAF receptor blocking must remain specu-
lative. In the autologous phase of NTN renal function deterio-
ration is associated with the presence of fibrin in the extra-
vascular space with the development of proliferative lesions
that induce a progressive obliteration of capillary lumens. Thus
PAF blocking might be effective because it reduces fibrin in
Bowman's space, a mechanism that has also been proposed to
explain the favorable effect of defibrination with Ancrod in the
same model [11, 33].
Why a molecule which antagonizes PAF activity reduces
fibnn formation at glomerular level cannot be ascertained on the
basis of the experiments presented here. A possible interpreta-
tion of these findings derives from recent studies suggesting that
macrophages might have a pivotal role in promoting fibrin
formation in rabbit nephrotoxic nephritis [7, 13]. The main
arguments in favor of this interpretation are that in the autolo-
gous phase of the disease, fibrin deposition is associated with
glomerular macrophage accumulation and that the maneuvers
that limit glomerular macrophage infiltration also prevent fibrin
deposition [8, 13]. Thus PAF antagonist might limit glomerular
fibrin formation because it inhibits macrophage accumulation
within glomeruli of rabbits with proliferative glomerulonephri-
tis. In inflammatory processes other than glomerulonephritis,
macrophages have been found to trigger fibrin deposition via
their expression of procoagulant activity which activates the
extrinsic pathway of coagulation [34, 35]. Some very recent
works suggest that also in proliferative glomerulonephritis
macrophages, through their ability to express procoagulant
activity, may be directly responsible for glomerular fibrin
deposition. Evidence to support this concept has been obtained
in an accelerated [14] and in a passive form of rabbit
nephrotoxic nephritis [13]. In this latter model data are now
available as to indicate that macrophage depletion abrogates
glomerular fibrin deposition and that lysates of isolated
glomeruli containing macrophages have higher procoagulant
activity than lysates of glomeruli without macrophages [13].
Altogether these results suggest that in the autologous phase of
nephrotoxic nephritis, the activation of macrophages infiltrating
the glomerular tuft promotes fibrin deposition through the
expression of their procoagulant activity. Although the signal
for macrophage infiltration and activation has not been estab-
lished, the present results seem to indicate that PAF is a likely
candidate. This possibility is reinforced by recent studies show-
ing that PAF directly activates procoagulant activity in rabbit
platelets [36].
Although made unlikely by the consistent results obtained
with two different antagonists, the possibility that the protective
effects observed in this study are due to some unstudied
interference with the underlying immune mechanisms of the
model itself can not be ruled out, given the non-quantitative
nature of the immunofluorescence technique. In conclusion we
have shown that PAF receptor antagonist favorably influences
the evolution of anti-glomerular basement membrane nephritis
in rabbits. The fact that these results have been obtained also by
the use of a structurally analogue of L-652,731, L-653,150,
strongly suggests that the beneficial effect of these molecules is
due to their ability to antagonize the PAF receptor. These
compounds might exert their effects by preventing the
macrophage accumulation and the macrophage—dependent
expression of procoagulant activity, inhibiting in turn glomeru-
lar fibrin deposition. The definite proof that PAF mediates
glomerular damage in NTN should include the evidence that in
vivo the development of the disease is associated with PAF
release from the kidney into systemic circulation.
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